Aardvark Therapeutics, Inc. (NASDAQ:AARD) Stock Has Consensus Target Price of $13.12 According to Brokerages

Aardvark Therapeutics, Inc. (NASDAQ:AARD) has received a consensus rating of “Hold” from the eleven brokerages that are covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $11.89.

A number of research firms have weighed in on AARD. Weiss Ratings reissued a “sell (d-)” rating on shares of Aardvark Therapeutics in a report on Tuesday, September 29th. HC Wainwright reduced their price objective on shares of Aardvark Therapeutics from $6.00 to $4.00 and set a “neutral” rating for the company in a research report on Monday. BTIG Research restated a “neutral” rating on shares of Aardvark Therapeutics in a report on Monday, October 12th. UBS Group set a $4.00 target price on Aardvark Therapeutics in a research report on Monday. Finally, Wall Street Zen upgraded Aardvark Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th.

Aardvark Therapeutics Stock Performance

Shares of NASDAQ AARD opened at $3.90 on Friday. Aardvark Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $16.60. The firm has a market capitalization of $85.33 million, a PE ratio of -1.21 and a beta of 3.80. The stock’s 50-day simple moving average is $5.45 and its 200-day simple moving average is $5.29.

Aardvark Therapeutics (NASDAQ:AARD) last posted its earnings results on Tuesday, August 11th. The company reported ($0.66) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.21. On average, sell-side analysts forecast that Aardvark Therapeutics will post -3.17 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Aardvark Therapeutics news, insider Nelson Sun sold 62,000 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $5.18, for a total value of $321,160.00. Following the completion of the sale, the insider owned 35,475 shares in the company, valued at approximately $183,760.50. The trade was a 63.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 17.80% of the company’s stock.

Institutional Investors Weigh In On Aardvark Therapeutics

Several large investors have recently modified their holdings of AARD. Bank of New York Mellon Corp increased its holdings in shares of Aardvark Therapeutics by 30.8% in the 1st quarter. Bank of New York Mellon Corp now owns 29,320 shares of the company’s stock valued at $111,000 after acquiring an additional 6,905 shares during the period. Susquehanna International Group LLP purchased a new stake in Aardvark Therapeutics in the 2nd quarter valued at $138,000. Ieq Capital LLC purchased a new stake in Aardvark Therapeutics in the 2nd quarter valued at $221,000. J. Goldman & Co LP purchased a new stake in Aardvark Therapeutics in the 2nd quarter valued at $233,000. Finally, Renaissance Technologies LLC purchased a new stake in Aardvark Therapeutics in the 1st quarter valued at $267,000.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in San Diego, California. The company develops novel therapies for obesity and other metabolic diseases, with a focus on treatments designed to regulate appetite and food intake.

Its lead investigational product, AARD-001, is an orally administered small-molecule candidate intended to activate bitter taste receptors and stimulate signaling pathways in the gastrointestinal tract that may influence appetite and satiety.